The University of Texas Rio Grande Valley Background
Due to poor survival rate associated with aggressive cancers like basal-like breast cancer (BBC) and glioblastoma multiforme (GBM), no current technology exists that can efficaciously treat BBC and GBM cancers.
This technology is a targeted therapy for aggressive cancers: basal-like cancer (BBC) and glioblastoma multiforme (GBM). Treatment with AS1842856 was found to induce cell death in a set of cancer lines, BBC: BT 549 and MDA-MB-468 as well as GBM: LN229, DBTRG, A172 and LN18.
A set of cancer lines were treated with AS 1842856 as a therapy for BBC and GBM. Results provided evidence of reduced cell numbers, induction of apoptotic genes and induction of apoptosis by membrane permeability (PI staining) and membrane depolarization (Annexin V FITC staining) by flow cytometric analysis ().
Stage of Development
Prototyping and characterization.
Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172, LN 18, HCT116 and SW480 led to reduced colony formation.
Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172, LN 18, and HCT116 led to apoptotic gene induction.
Treatment induced apoptosis as assessed by flow cytometric analysis in BT549 and LN229 cancer cell lines.
FOXO1 inhibition is proposed as a targeted therapy to treat aggressive cancers like BBC and GBM The therapy is effective by reducing cell number, induction of apoptotic genes, and induction of apoptosis